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In the present study the effect of phosphatidylinositol 4,5-bisphosphate (PIP2) was studied
on a native TRPC1 store-operated channel (SOC) in freshly dispersed rabbit portal vein
myocytes. Application of diC8-PIP2, a water soluble form of PIP2, to quiescent inside-out
patches evoked single channel currents with a unitary conductance of 1.9 pS. DiC8-PIP2-evoked
channel currents were inhibited by anti-TRPC1 antibodies and these characteristics are identical
to SOCs evoked by cyclopiazonic acid (CPA) and BAPTA-AM. SOCs stimulated by CPA,
BAPTA-AM and the phorbol ester phorbol 12,13-dibutyrate (PDBu) were reduced by anti-PIP2
antibodies and by depletion of tissue PIP2 levels by pre-treatment of preparations with
wortmannin and LY294002. However, these reagents did not alter the ability of PIP2 to activate
SOCs in inside-out patches. Co-immunoprecipitation techniques demonstrated association
between TRPC1 and PIP2 at rest, which was greatly decreased by wortmannin and LY294002.
Pre-treatment of cells with PDBu, which activates protein kinase C (PKC), augmented SOC
activation by PIP2 whereas the PKC inhibitor chelerythrine decreased SOC stimulation by PIP2.
Co-immunoprecipitation experiments provide evidence that PKC-dependent phosphorylation
of TRPC1 occurs constitutively and was increased by CPA and PDBu but decreased by
chelerythrine. These novel results show that PIP2 can activate TRPC1 SOCs in native
vascular myocytes and plays an important role in SOC activation by CPA, BAPTA-AM and
PDBu. Moreover, the permissive role of PIP2 in SOC activation requires PKC-dependent
phosphorylation of TRPC1.
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In vascular smooth muscle canonical transient receptor
potential (TRPC) channels are involved in many
physiological responses including contraction, cell
growth, proliferation and migration (see Large, 2002;
Beech et al.2004; Firth et al.2007).Akeyquestionconcerns
the activation mechanism of TRPC channels, which
are frequently described as either receptor-operated or
store-operated channels (ROCs and SOCs, respectively).
In freshly dispersed vascular myocytes TRPC ROCs
are stimulated by G-protein-coupled agonists such as
noradrenaline, angiotensin II (Ang II) or endothelin-1
(ET-1) coupled to either phospholipase C (PLC, TRPC6
in rabbit portal vein, Inoue et al. 2001; mesenteric artery,
Saleh et al. 2006; TRPC3/TRPC7 in rabbit coronary
artery, Peppiatt-Wildman et al. 2007) or phospholipase
D (TRPC3 in rabbit ear artery, Albert et al. 2005, 2006).
In all these cases it seems that diacylglycerol (DAG)
which is produced by phospholipase stimulation plays an
important role in channel activation and may actually
be the gating molecule (Albert & Large, 2006; Albert
et al. 2008). SOCs are activated by depletion of intra-
cellular Ca2+ stores and there is now considerable evidence
that TRPC proteins also form SOCs in native vascular
smoothmuscle with both TRPC1 andTRPC5 as suggested
components of SOCs (Xu & Beech, 2000; Xu et al. 2006;
Saleh et al. 2006, 2008). In vascular smoothmuscle protein
kinase C (PKC) appears to have an important role in
activation of TRPC SOCs (Albert & Large, 2002b; Albert
et al. 2007). In addition Ca2+-independent phospholipase
A2 has also been suggested to be involved in activating
SOCs (Smani et al. 2004).
Phosphatidylinositol 4,5-bisphosphate (PIP2) is an
important signalling molecule, which is cleaved by PLC
to inositol 1,4,5-trisphosphate (IP3) and DAG and both
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these products have well established cellular effects.
However, recently there has been much interest in the
direct actions of PIP2 on ion channels, including TRP
channels (Suh & Hille, 2005; Hardie, 2007; Rohacs, 2007;
Voets & Nilius, 2007; Nilius et al. 2008). In HEK293
cells PIP2 increased activity of expressed TRPC3, TRPC6
and TRPC7 channel activity (Lemonnier et al. 2008),
decreased TRPC4α activity (Otsuguro et al. 2008) and
produced complex effects on TRPC5 channels (Trebak
et al. 2008). In freshly dispersed vascular myocytes we
demonstrated that endogenous PIP2 inhibited native
TRPC6 channels (Albert et al. 2008). These data indicated
that PIP2 was bound to TRPC6 in unstimulated cells and
following receptor stimulation by Ang II, optimal channel
stimulationwas produced by hydrolysis of this boundPIP2
and simultaneous activation of TRPC6 channels by DAG,
possibly at the same PIP2-binding site on the channel
molecule (Albert et al. 2008).
In the present study we investigated the role of PIP2
in activation of native TRPC1 SOCs in rabbit portal vein
myocytes, which have characteristics of a heterotetrameric
channel consisting of TRPC1/TRPC5/TRPC7 subunits
(Saleh et al. 2008). These results show that PIP2 stimulates
this ion channel and that there is an obligatory role for
endogenous PIP2 in TRPC1 SOC activation.
Methods
Cell Isolation
New Zealand White rabbits (2–3 kg) were killed using I.V.
sodium pentobarbitone (120mg kg−1, in accordance with
the UK Animals Scientific Procedures Act, 1986). Portal
vein was dissected free from fat and connective tissue and
enzymaticallydigested into singlemyocytesusingmethods
previously described (Saleh et al. 2006).
Electrophysiology
Single cation currents were recorded with an HEKA
EPC8 patch-clamp amplifier (HEKA Instruments Inc.,
Bellmore,NY,USA) at room temperature (20–23◦C)using
cell-attached and inside-out patch configurations (Hamill
et al. 1981) and data acquisition and analysis protocols
as previously described (Saleh et al. 2006). Briefly, single
channel current amplitudeswere calculated from idealized
traces that were filtered off-line at 100 Hz with an 8-pole
Bessel filter (Frequency Devices, Haverhill, MA, USA)
and sampled at 1 kHz. Traces of at least 60 s in duration
were used to calculate open probability and construct
fitted-level amplitude histograms and events lasting for
< 6.664ms (2 × rise time for a 100 Hz, −3 db, low pass
filter)were excluded fromanalysis using the50%threshold
method. Figure preparation was carried out using Origin
6.0 (OriginLab Corp., Northampton, MA, USA) where
inward single channel currents are shown as downward
deflections. Open probability (NPo) was calculated using
the equation:
NPo =
∑
(Onn)
T
where n is number of simultaneously open channels in the
patch, On is time spent at the open level for each channel
(i.e. n − 1) and T is total recording time.
The relationship between NPo and PIP2 concentration
([PIP2]) for inside out patches was fitted with the Hill
equation: y = ymax
(1+K d/[PIP2])nH where ymax =maximumNPo,
K d is the apparent dissociation constant and nH is the Hill
coefficient.
Immunoprecipitation and Western blotting
Total cell lysate (TCL) was extracted and quantified as
previously described (Saleh et al. 2008). The immuno-
precipitation protocol was carried out using the Catch
andRelease R© kit (Upstate Biotechnology, Lake Placid, NY,
USA), where spin columns were loaded with 300–600μg
of cell lysates, 2–4μg of antibody, 2μg of β-actin anti-
body, and immunoprecipitated on an end-over-end stirrer
for 2 h at room temperature.
Protein samples were eluted with Laemmli sample
buffer and incubated at 60◦C for 5min. One-dimensional
protein gel electrophoresis, semi-dry transfer and
Western blot procedures were performed as previously
described (Saleh et al. 2008). Whenever possible,
alternative antibodies raised against different epitopes
were used for immunoprecipitation and Western blot
analysis. Secondary horseradish peroxidase-conjugated
goat anti-rabbit, goat anti-mouse (Sigma) and donkey
anti-goat (Millipore) antibodies were added according
to the host species of the primary antibody used
for the Western blot and subsequently detected with
ECL reagents (Saleh et al. 2008). In loading control
experiments anti-β-actin antibodies (mouse monoclonal,
Sigma,UK)were also added to the immunoprecipitate and
immunoblot procedures to show that expression levels
of β-actin did not change during the experimental
conditions. Moreover immunoblot control data showed
that anti-PIP2 and anti-TRPC1 antibodies did not
recognize β-actin following immunoprecipitation with
only anti-β-actin antibodies. Data shown represent
n-values of at least three separate experiments.
Anti-TRPC1, anti-PIP2 and anti-phosphoserine/
threonine antibodies
Polyclonal antibodies for TRPC1 raised against different
intracellular epitopes were purchased from Santa Cruz
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Biotechnology (Santa Cruz, CA, USA) and Alomone
Laboratories (Jerusalem, Israel). The specificity of these
antibodies for their target proteins have been previously
confirmed (Liu et al. 2005b; Sours et al. 2006). Mouse
monoclonal PIP2 antibody generated against liposomes of
humanorigin constitutedwith thephospholipid (Osborne
et al. 2001) was purchased from Assay Designs (Ann
Arbor, MI, USA) and Santa Cruz Biotechnology and
has a predicted molecular mass of 74 kDa according
to the manufacturer’s specifications. This anti-PIP2
antibody has previously been used in electrophysiological
(Liou et al. 1999; Bian et al. 2001; Ma et al. 2002; Pian
et al. 2006; Xie et al. 2008) and immunoprecipitation
experiments (Asteggiano et al. 2001; Beauge et al. 2002;
Yue et al. 2002) to investigate the role of PIP2 in regulating
ion channels and exchangers. Anti-phosphoserine and
anti-phosphothreonine antibodies were purchased from
Santa Cruz Biotechnology and both were used together in
immunoprecipitation andWestern blotting experiments.
Solutions and drugs
In cell-attached patch experiments the membrane
potential was set to 0mV by perfusing cells in a KCl
external solution containing (mM): KCl (126), CaCl2
(1.5), Hepes (10) and glucose (11), pH to 7.2 with 10 M
KOH. Nicardipine (5μM) was also included to prevent
smooth muscle cell contraction by blocking Ca2+ entry
through voltage-dependent Ca2+ channels. Immediately
prior to patch excision for inside-out recordings and
within a 30 s period the bathing solution was exchanged
for an intracellular solution containing (mM): CsCl
(18), caesium aspartate (108), MgCl2 (1.2), Hepes (10),
glucose (11), BAPTA (1), CaCl2 (0.48, free internal Ca2+
concentration approximately 100 nM as calculated using
EqCal software; Biosoft, Great Shelford, UK), Na2ATP (1),
NaGTP (0.2) pH 7.2 with Tris. U73122 at 2μM and 50 nM
wortmannin were also included for all experiments with
diC8-PIP2 to prevent conversion of PIP2 into IP3, DAG
and phosphatidylinositol 3,4,5-trisphosphate (PIP3).
The patch pipette solution used for both cell-attached
and inside-out patch recording (extracellular solution)
was K+ free and contained (mM): NaCl (126), CaCl2
(1.5), Hepes (10), glucose (11), TEA (10), 4-AP (5),
iberiotoxin (0.0002), DIDS (0.1), niflumic acid (0.1)
and nicardipine (0.005), pH to 7.2 with NaOH. Under
these conditions VDCCs, K+ currents, swell-activated Cl−
currents and Ca2+-activated conductances are abolished
and non-selective cation currents could be recorded in
isolation.
DiC8-PIP2 was from Cayman Chemical Co. (Ann
Arbor, MI, USA) whilst all other drugs were purchased
from Calbiochem (UK), Sigma (UK) or Tocris Bioscience
(Bristol, UK). Reagents were dissolved in distilled H2O
or DMSO (0.1%) and DMSO alone had no effect on
SOC activity. The values are the mean of n cells ± S.E.M.
Statistical analysis was carried out using Students’ t test for
paired (comparing effects of agents on the same cell) or
unpaired data (comparing effects of agents between cells)
with the level of significance set at P < 0.05.
Results
DiC8-PIP2 activates TRPC1 SOCs in rabbit portal
vein myocytes
In the first series of experiments we investigated the
effect of exogenous diC8-PIP2, a water-soluble form of
PIP2, on cyclopiazonic acid (CPA)-evoked SOC activity
in inside-out patches. In these experiments we initially
evoked SOC activity by bath applying the sarcoplasmic
reticulum (SR) Ca2+-ATPase inhibitor CPA (10μM) to
cell-attached patches and when channel activity reached
plateau levels patches were excised into the inside-out
configuration. SOC activity was maintained in excised
patches for periods of up to 45min and did not
run down in the presence of ATP and GTP. This
configuration allowed diC8-PIP2 to be bath applied to the
cytosolic surface of the patches. Figure 1A shows that bath
application of 10μM diC8-PIP2 to inside-out patches
significantly increased mean open probability (NPo) of
CPA-evoked SOC activity from 0.18± 0.05 to 0.37± 0.07
at −80mV (n = 5, P < 0.05) and this effect was readily
reversed following the removal of diC8-PIP2 (not shown).
The bathing solution also contained 2μM U73122 and
50 nM wortmannin (see Methods) to ensure that this
was an effect of PIP2 itself and not a metabolite.
Channel current amplitude histograms shown in Fig. 1B
illustrate that CPA-evoked channel currents had similar
peak amplitudes in the absence (Fig. 1Ba) and presence
(Fig. 1Bb) of diC8-PIP2, which suggests that diC8-PIP2
increased activity of the same CPA-induced channels.
To investigate whether diC8-PIP2-induced increases
in SOC activity were due to either potentiation of
CPA-evoked responses or direct activation of SOCs, we
studied the effect of diC8-PIP2 on quiescent inside-out
patches in the presence of 2μM U73122 and 50 nM
wortmannin. Figure 1C andD shows that bath application
of 10μM diC8-PIP2 to an inside-out patch activated
channel currents which had a mean NPo of 0.27± 0.04
(n = 16) at −80mV and a slope conductance between
−50mV and −120mV of 1.9 pS. These data indicate
that diC8-PIP2 activates channel currents with a similar
conductance to that of native TRPC SOCs previously
described in portal vein myocytes (Albert & Large, 2002a;
Saleh et al. 2008). TRPC1 has been previously proposed to
be a component of SOCs in portal vein myocytes (Saleh
et al. 2008) and Fig. 1C shows that bath application of
an anti-TRPC1 antibody (1 : 200 dilution) significantly
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inhibited diC8-PIP2-induced channel activity by 76± 6%
at –80mV (n = 5,P < 0.01). This inhibitionwas abolished
when the antigenic peptide (also 1 : 200 dilution) was
preincubated with the antibody (n = 5, data not shown).
Effect of an anti-PIP2 antibody on SOC activity
The above results indicate that exogenous diC8-PIP2
activates ion channels with properties similar to TRPC1
SOCs previously described in portal vein myocytes (cf.
Albert & Large, 2002a; Saleh et al. 2008). Therefore we
investigated the roleof endogenousPIP2 in activating these
SOCs by studying the effect of an anti-PIP2 antibody on
SOCs in inside-out patches.
In the first experiments SOC activity was induced
in cell-attached patches by CPA or BAPTA-AM and
then patches were excised and anti-PIP2 antibodies were
applied to the internal membrane surface of the patches.
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Figure 1. diC8-PIP2 activates TRPC1 SOCs in rabbit portal vein myocytes
A, bath application of 10 μM CPA evoked SOC activity in a cell-attached patch held at −80 mV. After excision
into the inside-out configuration, SOC activity was potentiated by bath application of 10 μM diC8-PIP2. B, fixed
level channel current amplitude histograms of SOC activity shown in A. Histograms could be fitted by the sum
of several Gaussian curves showing the presence of more than one channel in the patch. Note that the peaks
of the Gaussian curves have similar values in the absence (a) and presence of diC8-PIP2 (b) indicating that this
phospholipid increased the activity of the same channel. C, bath application of 10 μM diC8-PIP2 activated channel
currents in a quiescent inside-out patch held at −80 mV which were inhibited by anti-TRPC1 antibodies (Santa
Cruz, 1 : 200 dilution). D, diC8-PIP2-induced channel currents had a slope conductance of 1.9 pS between −120
and −50 mV.
Figure 2Aa and b and B shows that mean NPo of
SOC activity, initially induced by 10μM CPA or 50μM
BAPTA-AM, was significantly inhibited by anti-PIP2
antibodies (1 : 200 dilution) by 91± 3% (n = 7) and
82± 9% (n = 7), respectively. This effect was not seen
when the anti-PIP2 antibody was denatured prior to
application by boiling for a period of 30min (n = 4,
data not shown). In addition Fig. 2Ac and B show that
anti-PIP2 antibodies also produced marked inhibition
of SOC activity induced by the PKC-activating phorbol
ester phorbol 12,13-dibutyrate (PDBu, 1μM), which
has been previously shown to activate SOCs in this
preparation (Albert & Large, 2002b; Saleh et al. 2008).
In these experiments inside-out patches were prepared
from quiescent cells before application of PDBu and
anti-PIP2 antibodies, which significantly reduced activity
by 92± 2% (n = 5). Figure 2C shows that tissue lysates
from portal vein immunoprecipitated with anti-TRPC1
C© 2009 The Authors. Journal compilation C© 2009 The Physiological Society
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antibodies then Western blotted with anti-PIP2
antibodies detected a band of ∼70 kDa, which is the
predicted band for the PIP2 complex with this anti-
body (see Methods). Moreover Fig. 2C shows that
preincubation of anti-TRPC1 antibodies with its
antigenic peptide (AgP) reduced detection of the band
with anti-PIP2 antibodies without affecting expression
levels of β-actin proteins.
Agents that deplete PIP2 levels inhibit SOC activity
These data suggest that endogenous PIP2 associated
with TRPC1 proteins may have an important role in
activating SOCs in portal vein myocytes. Therefore we
investigated the effect of depleting endogenous PIP2 levels
on SOC activity in cell-attached patches. To deplete
PIP2 we used 20μM wortmannin and 100μM LY294002
which at these concentrations inhibit phosphoinositol
(PI)-4-kinases leading to a reduction in generation of PIP2
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Figure 2. Anti-PIP2 antibodies inhibit TRPC1 SOC activity
A, bath application of anti-PIP2 antibodies (1 : 200 dilution) to the cytosolic surface of inside-out patches held at
–80 mV markedly inhibited SOC activity initially induced by 10 μM CPA (a) or 50 μM BAPTA-AM (b) in cell-attached
patches and 1 μM PDBu (c) applied to a quiescent inside-out patch. B, mean data showing that anti-PIP2 antibodies
significantly reduced SOC activity evoked by CPA, BAPTA-AM and PDBu (∗P < 0.05). C, co-immunoprecipitation
experiments where tissue lysates from portal vein were immunoprecipitated (IP) with an anti-TRPC1 antibody
(Santa Cruz) and then Western blotted (WB) with an anti-PIP2 antibody. In control conditions a band of ∼70 kDa
was observed (see Methods), which was absent after pre-treatment of the anti-TRPC1 antibody with its antigenic
peptide (AgP). Note that bands detected with an anti-β-actin antibody were unaffected by pretreatment with the
antigenic peptide.
and consequently a depletion of tissue PIP2 levels (Suh &
Hille, 2005; Albert et al. 2008).
Figure 3Aa and b shows that pretreatment of portal
vein myocytes with 20μM wortmannin for 15min almost
obliterated the ability of CPA and PDBu to induce SOC
activity, and mean NPo was decreased by 98± 1% (n = 8)
and 97± 2% (n = 9), respectively, compared to untreated
control cells (n = 6 and n = 5). Moreover Fig. 3Ac shows
that pretreatment of myocytes with 100μM LY294002 for
15min also reduced NPo of CPA-induced SOC activity by
a mean value of 99± 1% (n = 6) compared to control
cells (n = 6). However Fig. 3Aa–c shows that in cells
pretreated with wortmannin or LY294002, bath
application of 10μM diC8-PIP2 in the inside-out
configuration was still able to induce SOC activity. In
the presence of wortmannin mean NPo of CPA- and
PDBu-induced SOC activity was significantly increased by
diC8-PIP2 from, respectively, 0.02± 0.01 to 0.29± 0.07
(n = 4, P < 0.05) and 0.02± 0.01 to 0.51± 0.09 (n = 5,
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P < 0.05). In addition, in the presence of LY294002
the mean NPo of CPA-evoked SOC activity was
significantly enhanced from 0.01± 0.01 to 0.12± 0.05
(n = 3, P < 0.05) by diC8-PIP2.
To confirm that wortmannin and LY294002 lowered
PIP2 levels we carried out co-immunoprecipitation
and Western blotting studies. Figure 3Ba shows that
pretreatment of portal vein tissuewith 20μMwortmannin
reduced total PIP2 levels measured with Western blotting
(Fig. 3Ba left panel) and following immunoprecipitation
(Fig. 3Ba right panel). In addition Fig. 3Bb illustrates
that pre-treatment of portal vein tissue with 20μM
wortmannin did not alter expression levels of TRPC1
proteins, which were detected as bands at a molecular
mass of∼90 kDa (seeMethods). Moreover Fig. 3Bc shows
that pretreatment of portal vein tissue with either 20μM
wortmannin or 100μM LY294002 predictably reduced
association of PIP2 with TRPC1 proteins.
10 μM PIP21 μM PDBu
10 μM CPA 10 μM PIP2
20 μM Wortmannin
WB: TRPC1
IP: PIP2
10 μM CPA 10 μM PIP2
100 μM LY294002
20 μM Wortmannin
WB: PIP2 WB: PIP2
IP: PIP2
20 μM
Wort.
20 μM
Wort.
20 μM
Wort.
20 μM
Wort.
100 μM
LY
20 μM
Wort.
0.2 pA
60 s
β-actin
70 kDa
90 kDa
WB: TRPC1 WB: TRPC1
IP: TRPC1
Aa
b
c
Ba
b
c
Inside-out
Inside-out
70
35
100
kDa
Figure 3. Depletion of endogenous PIP2 inhibits SOC activity
A, pre-treatment of portal vein tissue with 20 μM wortmannin for 15 min prevented SOC activation by 10 μM CPA
(a) in cell-attached patches and 1 μM PDBu (b) in inside-out patches held at –80 mV. Pre-treatment with 100 μM
LY294002 also inhibited SOC activity induced by CPA in a cell-attached patch held at –80 mV (c). Note that in
inside-out patches diC8-PIP2 activated SOC activity in the presence of wortmannin (a and b) and LY294002 (c).
Ba, pre-treatment of tissue lysates from portal vein with 20 μM wortmannin for 15 min reduced total PIP2 levels
detected with WB (left panel) and following IP and WB (right panel) using anti-PIP2 antibodies. Bb, pre-treatment
with 20 μM wortmannin had no effect on expression levels of TRPC1 detected with WB and following IP and WB
using anti-TRPC1 antibodies (Santa Cruz). Bc, co-immunoprecipitation experiment showing that pre-treatment of
portal vein tissue with 20 μM wortmannin and 100 μM LY294002 inhibited association of PIP2 with TRPC1 proteins
following IP with anti-PIP2 and WB with anti-TRPC1 antibodies.
These results provide powerful evidence that end-
ogenous PIP2 is obligatory for SOC activation by CPA
and PDBu in portal vein myocytes. Moreover these data
indicate that interactions between TRPC1 proteins and
PIP2 have an important role in stimulating SOC activity.
Protein kinase C regulates diC8-PIP2-induced
activation of SOCs
We have previously shown that PKC inhibitors
chelerythrine and Ro 31-8220 inhibit SOCs activated
by CPA, PDBu and BAPTA-AM in rabbit portal vein
myocytes (Albert & Large, 2002b; Liu et al. 2005a) and in
other vascular preparations (Saleh et al. 2006, 2008).As the
present work indicates that PIP2 is also obligatory for SOC
activation we investigated whether these two pathways
were dependent on one another or could activate SOCs
independently.
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Figure 4Aa and b compares control responses to
diC8-PIP2 to responses in cells pretreated with 1μM
PDBu, a PKC activator, for 15min in inside-out
patches held at –80mV. These data show that mean
NPo of SOC activity induced by 10μM diC8-PIP2
was significantly increased from 0.27± 0.04 (n = 16)
to 0.72± 0.15 (n = 5, P < 0.01) in the presence of
PDBu. Figure 4Ac shows that the same experiment
done in reverse, i.e. PDBu applied after PIP2, also
enhanced PIP2-evoked SOC activity from 0.33± 0.06 to
0.86± 0.14 (n = 6, P < 0.01). In contrast pre-application
of the PKC inhibitor chelerythrine greatly reduced the
ability of 10μM diC8-PIP2 to activate SOCs (Fig. 4Ad
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Figure 4. PKC-dependent phosphorylation associated with TRPC1 proteins is pivotal for activation of
SOC activity by diC8-PIP2
Aa, control response of 10 μM diC8-PIP2 applied to the internal surface of an inside-out patch. b, 1 μM PDBu
greatly enhanced responses to diC8-PIP2 in patches held at –80 mV. c, a representative trace where 10 μM
diC8-PIP2 was applied to an inside-out patch first and subsequent addition of PDBu potentiated channel activity.
d, pre-incubation with 3 μM chelerythrine almost completely abolished the ability of diC8-PIP2 to activate SOCs.
B, mean concentration–response curves of diC8-PIP2-induced SOC activity in inside-out patches held at –80 mV
fitted with Hill plots (see Methods) in control conditions and in the presence of PDBu and chelerythrine. In the
presence of 1 μM PDBu the diC8-PIP2-evoked increase in NPo was obtained by subtracting the value in PDBu
alone from the NPo in PDBu plus diC8-PIP2. Note that the EC50 values of the concentration–response curves in
control conditions and in the presence of PDBu are similar ∼3 μM. Each point is from at least n = 4, ∗P < 0.05.
C, co-immunoprecipitation experiments showing that pre-treatment of portal vein tissue with 10 μM CPA and
1 μM PDBu increases phosphorylated serine and threonine residues on TRPC1 proteins detected on Western blots.
Note that CPA- and PDBu-evoked increases in TRPC1 phosphorylation are inhibited by pre-incubation with 3 μM
chelerythrine.
and B. Figure 4B shows mean concentration–response
curves of diC8-PIP2-activated SOCs in control conditions
and following pre-treatment with either PDBu or
chelerythrine, and clearly illustrates that PDBu increased
mean NPo of diC8-PIP2-induced SOC activity at all
concentrations tested and produced a larger maximum
response. Interestingly, the concentration–response
curves of diC8-PIP2-induced SOC activity had similar
nH values of 1.7 and 1.6 in the absence and presence of
PDBu, respectively,whilst theEC50 valueswere also similar
in all conditions, around 3μM. Thus the major effect of
PDBu appears to be an increase in the number of available
channels in the normal concentration range of PIP2.
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Protein kinase C-dependent phosphorylation of
TRPC1
These data with chelerythrine indicate that constitutive
PKC activity is required for activation of SOCs by
diC8-PIP2 and that increased PKC stimulation augments
diC8-PIP2 induced activation of SOCs. Therefore we
investigated the effect of agents that activate SOC activity
on PKC-dependent phosphorylation of TRPC1 proteins
and also their effect on PIP2 interactions with TRPC1
proteins using immunoprecipitation methods.
Figure 4C shows that unstimulated tissue lysates
from portal vein immunoprecipitated with both
anti-phosphoserine and -threonine antibodies then
blotted with anti-TRPC1 detected a band of ∼90 kDa.
In addition Fig. 4C shows that pre-treatment of tissue
lysateswith10μMCPAand1μMPDBu increased intensity
of the TRPC1 protein bands, which were inhibited by
pre-incubation with 3μM chelerythrine. Pre-treatment
with 20μM wortmannin had no effect on unstimulated,
CPA- or PDBu-induced phosphorylation of TRPC1
proteins (data not shown). Interestingly pre-treatment of
tissue lysates from portal vein with 10μM CPA or 1μM
PDBu for 15min did not alter the level of association
between TRPC1 proteins and PIP2 (data not shown).
These data indicate that TRPC1 proteins are constitutively
phosphorylated and that this phosphorylation can be
increased by CPA and PDBu.
These co-immunoprecipitation data together with
functional studies suggest that CPA and PDBu increase
PKC-dependent phosphorylation of TRPC1 proteins,
which promotes PIP2-mediated SOC activity.
Discussion
The results from the present study show that PIP2 activates
a TRPC1 SOC in freshly dispersed rabbit portal vein
smooth muscle cells. In addition, evidence is presented
which indicates that endogenous PIP2 is required for SOC
activation in response to agents that deplete intracellular
Ca2+ stores. To our knowledge these findings are the first
to report that PIP2 activates a native TRPC1 SOC.
We initially found that PIP2 augmented SOC activity
when applied to the cytosolic surface of patches where
activity had been first induced by the Ca2+-ATPase
inhibitor CPA. Subsequentlywe also found that PIP2 alone
applied to the cytosolic surface of a quiescent inside-out
patch readily activated the same 2 pS non-selective cation
channel. Moreover anti-TRPC1 antibodies inhibited
the PIP2-evoked channel activity as seen in previous
studies where the channel was activated by CPA and
BAPTA-AM (Saleh et al. 2008). These characteristics of
the PIP2-evoked channel are similar to the properties
of channel currents evoked by store-depletors previously
described in this preparation (Albert & Large, 2002a;
Liu et al. 2005a; Saleh et al. 2008). PIP2-evoked channel
currentswereobserved in thepresenceof thePLC inhibitor
U73122 and 50 nMwortmannin, which selectively inhibits
phosphoinositol-3-kinase. Consequently PIP2, and not a
metabolite, activates the ion channel, which has properties
of a TRPC1/TRPC5/TRPC7 heterotetramer (Saleh et al.
2008).
Role of endogenous PIP2 in SOC stimulation
Single channel activity evoked by CPA, BAPTA-AM or
PDBu was markedly inhibited by an anti-PIP2 anti-
body and this inhibitory effect was abolished when the
antibody was denatured. Moreover, the same anti-PIP2
antibody increased TRPC6 channel activity in rabbit
mesenteric artery myocytes where PIP2 had an inhibitory
role (Albert et al. 2008), which suggests that this is not
a non-selective effect of this antibody. Treatment with
high concentrations of wortmannin and LY294002, which
depleted total tissue PIP2 levels, almost obliterated SOC
channel activation by CPA and PDBu. However, in the
same cells, in the inside-out configuration PIP2 always
evoked SOC activity when applied to the internal surface
of the membrane indicating that the channels functioned
normally. Co-immunoprecipitation studies illustrated
that TRPC1 was associated with PIP2 in portal vein tissue,
whilst treatment with wortmannin or LY294002 depleted
both total tissue PIP2 levels and reduced co-association
between TRPC1 and PIP2. Together these results strongly
indicate an obligatory role for endogenous PIP2 in
activation of the TRPC1 SOC by store-depleting reagents
in portal vein myocytes.
Interaction between PIP2 and PKC on TRPC1 SOC
activation
We have previously shown that CPA-evoked SOCs in
the portal vein are dependent on PKC for activation
(Albert & Large, 2002b; Saleh et al. 2008). The pre-
sent work demonstrates that agents which affect PKC
activity had a profound effect on the ability of PIP2 to
activate SOCs. PIP2 produced a much larger increase in
channel NPo in cells pre-treated with a PKC activator
compared to control cells. Interestingly there was little
change in the concentration range at which PIP2 evoked
channel activity. Instead in the presence of PDBu effective
PIP2 concentrations produced greater channel activity
with an increased maximum response. These effects were
most likely to be due to an increase in the number of
active channels within the patch and not to channel
insertion since the experiments were carried out in the
inside-out configuration. Furthermore in cells pre-treated
with the PKC inhibitor chelerythrine there was marked
suppression of PIP2-evoked channel activity. These data
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indicate that PKC-dependent phosphorylation of the SOC
regulates the ability of PIP2 to activate the channel.
Co-immunoprecipitation experiments provided evidence
that TRPC1 is phosphorylated constitutively and that CPA
andPDBu increased the levels of TRPC1 phosphorylation.
Previously we have reported that the phosphatase
inhibitor calyculin A induced SOC activity also suggesting
constitutive phosphorylation of SOCs (Albert & Large,
2002b). Therefore our data suggest that the ability of
PIP2 to evoke the SOC depends on PKC-dependent
phosphorylation of TRPC1 and previously it has been
shown that PKCα-dependent phosphorylation of TRPC1
regulates store-operated Ca2+ entry in cultured endo-
thelial cells (Ahmmed et al. 2004). Interestingly TRPC1
co-associated with PIP2 in unstimulated cells and this
interaction did not appear to be increased by CPA or
PDBu. Therefore it is possible that PIP2 is tethered to
TRPC1 at rest but only activates the channel when TRPC1
is phosphorylated by PKC.
Recently several studies have implicated a role for
stromal interaction molecule-1 (STIM1) in the activation
of SOCs composed of TRPC1 and Orai1 complexes in
heterologous expression systems (Huang et al. 2006; Ong
et al. 2007; Yuan et al. 2007) and cultured smooth muscle
cells (Li et al. 2008). The roles of STIM-1 orOrai1 have not
been assessed in native vascular preparations but it will be
of future interest to see if portal vein SOCs are composed
of STIM1/TRPC1/Orai1 ternary complexes and whether
STIM1 can activate these channels in the absence of PIP2
or PKC phosphorylation.
Conclusions
This study shows that PIP2 activates a native SOC
with TRPC1 properties in vascular myocytes. Pre-
viously we postulated that this SOC may possess a
TRPC1/TRPC5/TRPC7 heteromeric structure. Moreover
it appears that endogenous PIP2 is obligatory for channel
activation by agents such as CPA, BAPTA-AM and
PDBu. Finally PIP2 stimulation of the SOC appears
to be regulated by PKC-dependent phosphorylation of
TRPC1 induced by procedures that deplete internal Ca2+
stores. In physiological conditions SOCs are activated
by G-protein-coupled receptor stimulation that often
utilizes PLC-mediated cleavage of PIP2 to produce IP3
and DAG. It seems curious that an agonist that decreases
the concentration of PIP2, which is essential for SOC
activation, is able to activate these channels (Albert
& Large, 2002b). It is possible that there are separate
microdomains of PIP2; one pool of PIP2 may be in
a complex with the pharmacological receptor and PLC
while a second pool of PIP2, which is not accessible to
PLC, may be linked to the TRPC1 SOC complex. Further
experiments are needed to test this hypothesis. It is clear
from the present work that endogenous PIP2 is required
for activation of TRPC1 SOC, in contrast to its effect on
TRPC6 ROC where PIP2 is an endogenous inhibitor of
channel activation by DAG (Albert et al. 2008).
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